Ignite Creation Date:
2025-12-25 @ 1:26 AM
Ignite Modification Date:
2026-02-23 @ 8:09 PM
Study NCT ID:
NCT02938793
Status:
TERMINATED
Last Update Posted:
2025-09-23
First Post:
2016-10-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
Sponsor:
Prisma Health-Upstate
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
ESR-15-11633
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None